"They are in a very difficult position," she said. "They are increasingly just looking at the cost, but the pressure from the public can be very powerful."
UK medical group rejects new skin cancer treatment →
"They actually reverse their decisions quite a lot," said Aparna Krishnan, a senior health care and pharmaceutical analyst at IHS Global Insight in London.
Be the first to know